2021
DOI: 10.1080/08923973.2021.1872619
|View full text |Cite
|
Sign up to set email alerts
|

Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer

Abstract: Background: Many clinical trials of immune checkpoint blockade-based combination therapies are under way. Vaccine therapy is a promising partner of combination therapies. We have developed a personalized peptide vaccination and conducted clinical trials of it in patients with various cancers. At the present time, we have only a limited number of biomarkers related to the prognosis of vaccinetreated patients. Thus, new biomarkers are urgently needed. Methods: In this study, we investigated the plasma cell-free … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 31 publications
0
4
0
Order By: Relevance
“…Collectively, our data indicated that ALU elements can be used as a biomarker (29,35,44,47,49,52,54,63). The use of cfDNA, for early diagnosis, prognosis biomarkers and monitoring of therapy have been a significant advancement in clinical medicine (18,47,51,52,(60)(61)(62).…”
Section: Discussionmentioning
confidence: 82%
See 1 more Smart Citation
“…Collectively, our data indicated that ALU elements can be used as a biomarker (29,35,44,47,49,52,54,63). The use of cfDNA, for early diagnosis, prognosis biomarkers and monitoring of therapy have been a significant advancement in clinical medicine (18,47,51,52,(60)(61)(62).…”
Section: Discussionmentioning
confidence: 82%
“…Higher cfDI values in cancer patients vs. healthy controls were identified in many studies (31,34,57,58,61). By contrast, lower cfDI was observed in different studies; however, some articles with a focus on metastatic breast cancer (10,45), recurrent breast cancer (46), or first cycle of vaccination (53,62) were few and inconsistent.…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, eight studies were found in PubMed ( (accessed on 9 August 2022)) following these criteria: “lung cancer”, “DNA vaccine”, article type “clinical trial”, from 2001 to 2022 [ 120 ]. Among these clinical trials, most of them concentrated on prophylactic DNA vaccine or molecular adjuvant against cancer [ 121 , 122 ]. For example, CpG ODN (K3), a novel synthetic DNA adjuvant, was used to boost the immune response in patients with lung cancer.…”
Section: Recent Clinical Trials Based On Dna Vaccines Against Lung Ca...mentioning
confidence: 99%
“…ALU is a 300bp non-long terminal repeat sequence abundant in human genome and widely used to detect cfDNA [30,31]. Recent studies have reported that the quantity and integrity of cfDNA (cfDI) in plasma can be a promising biomarker for multiple cancers [32][33][34] and inflammatory diseases [35]. We recently showed that cfDNA may be used for diagnosis and monitoring of atherosclerosis [36].…”
Section: Introductionmentioning
confidence: 99%